Sunshine Biopharma, Inc - FORM 10-K - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - March 30, 2021

Attached files

file filename
10-K - ANNUAL REPORT - Sunshine Biopharma, Incsbfm_10k.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Sunshine Biopharma, Incsbfm_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Sunshine Biopharma, Incsbfm_ex311.htm
 
Exhibit 32
 
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with this annual report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 30, 2021, (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1. 
The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: March 30, 2021
s/ Steve N. Slilaty

Steve N. Slilaty, Chief Executive Officer
 
 
Dated: March 30, 2021
/s/ Camille Sebaaly
 
Camille Sebaaly, Chief Financial Officer
 
 

Sunshine Biopharma, Inc Reports